The deal calls for Schein to lend BioHorizons about $145 million to fund a distribution to shareholders, followed by an equity investment. BioHorizons would continue to operate as an independent company, according to a regulatory filing. Other details of the agreement, expected to close by the end of the year, were not disclosed.
Birmingham, Ala.-based BioHorizons makes dental implants and employs about 325 workers, according to the filing, and posts annual revenues of roughly $115 million.
"Henry Schein’s strategy includes advancing our position in dental specialty markets, an integral part of which is to support those practitioners who perform oral surgery involving implants," chairman & CEO Stanley Bergman said in prepared remarks. "Implant dentistry is a critical element of the profession’s transition to digital dentistry. More and more abutments for implants are being digitally designed and fabricated, which increase patient comfort and esthetics and reduce patient visits. Customer demand for implants and the associated materials are expected to increase as digital processes are adopted and the dental experience for the patient is enhanced."
Schein said it expects the deal to dilute 2014 earnings per share by 3¢-5¢ and to add 3¢-4¢ to EPS in 2015. Diluted EPS for 2014 are now pegged at $5.32-$5.42, down from prior guidance of $5.37-$5.47.